Transvenous implantable defibrillators and cardiac resynchronization devices placed for primary prevention of sudden death and as a heart failure therapy for advanced systolic dysfunction in association with bundle branch block are now common therapies. Outside of clinical trials, long-term mortality outcomes are unknown. Additionally, newer-generation devices are enabled to transmit data daily from patients' homes with the use of a remote communicator, and these data are available to physicians on the Internet. This study provides 1-and 5-year survival outcome data in Ͼ194 000 device recipients with devices implanted from a single manufacturer and demonstrates that survival is equivalent to those patients studied in the pivotal randomized trials. One-and 5-year implantable cardioverter-defibrillator survival rates are 92% and 68%, respectively, and are 88% and 54% for cardiac resynchronization therapy defibrillators. Patients transmitting data remotely had the best survival, and shock therapies were associated with worsened survival in both implantable defibrillator and cardiac resynchronization device recipients. The 1-and 5-year risks of shock were 14% and 38% for implantable cardioverter-defibrillator recipients and were 13% and 33% for cardiac resynchronization therapy defibrillator subjects. Sensitivity analysis did not detect a significant imbalance between patients followed in traditional clinic settings compared with those transmitting data remotely as well as in the clinic. This is the largest report to date on survival after device implantation and finds that survival benefits observed over shorter follow-up intervals in clinical trials are maintained. This information is particularly important because there are upfront risks and costs associated with device implantation. See p 2359.
Long-Term Results of Catheter Ablation in Paroxysmal Atrial Fibrillation: Lessons From a 5-Year Follow-Up
Paroxysmal atrial fibrillation (AF) progresses toward chronic AF at an estimated rate of 15% to 30% over a 1-to 3-year period. Compared with paroxysmal AF, chronic AF is known to increase the incidence of death and heart failure and to have less success by catheter ablation. In the present study, we prospectively investigated the long-term outcome after circumferential pulmonary vein isolation in patients with paroxysmal AF. Our data demonstrated the highest rate of recurrence during the first 3 months, followed by a steady rate of recurrence throughout the 5-year follow-up period. The single-procedure success rate was 46.6%, with an additional 9.3% of patients demonstrating clinical improvement. The success rate after a median of 1 procedure (1 to 3) increased to 79.5%, whereas an additional 13.0% of patients experienced clinical improvement. Recovered pulmonary vein conduction was observed in 94.0% of patients during the second and in 66.7% of patients during the third procedure. In 7 of 8 patients with recovery of pulmonary vein conduction identified during the third procedure, the site of conduction gap was different from that noted during the second procedure, which was performed within 10 days after the initial procedure. Only 4 of 161 patients (2.4%) developed chronic AF over an Ϸ5-year follow-up period. Our study demonstrated that stable sinus rhythm can be achieved by circumferential pulmonary vein isolation with a median of 1 (1 to 3) procedure in the majority of patients with paroxysmal AF. Repeated procedures should be post-poned to unmask all potential conduction gaps 3 months after the initial procedure unless refractory arrhythmias occur during the blanking period. A low incidence of chronic AF after ablation was observed during Ϸ5 years of follow-up, which may suggest early intervention to prevent or delay the progression toward chronic AF. See p 2368.
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Atrial fibrillation (AF) is highly prevalent and associated with pronounced morbidity, mortality, and socioeconomic burden. AF accounts for more hospitalization days compared with other arrhythmias, can contribute to other arrhythmias, can exacerbate heart failure, and is a risk factor for ischemic stroke resulting from thromboembolism. A characteristic of both clinical and experimental AF is alterations in electrophysiology, promoting persistent AF even in the absence of progressive underlying heart disease, so-called atrial remodeling or "AF begets AF." Despite extensive research, AF remains a difficult clinical problem. In the present study, we report that a single microRNA (miRNA), miR-328, can contribute to a key component of the adverse electric remolding process leading to AF. miRNAs are a class of newly discovered endogenous Ϸ22-nt noncoding double-stranded RNAs that fine-tune expression of protein-coding genes, primarily repression of protein level. miR-328 is aberrantly upregulated in its expression level in patients with AF and in animal models of AF. This upregulation results in silencing of a gene critical to cardiac electric function; knockdown of miR-328 terminates AF. The study represents a detailed characterization of the role of a select miRNA in AF. Our findings suggest the potential of miR-328 as a target for AF management with normalization of miR-328 level for converting AF to sinus rhythm in the clinical setting. See p 2378.
Myocardial Infarction and Risk of Suicide: A Population-Based Case-Control Study
Myocardial infarction (MI) is associated with an increased risk of anxiety, depression, low quality of life, and all-cause mortality. Whether MI is associated with an increased risk of suicide is unknown. We conducted a population-based case-control study by retrieving data from 5 nationwide longitudinal registers in Denmark. As cases, we selected all persons aged 40 to 89 years who died by suicide from 1981 to 2006. As controls, we randomly selected up to 10 persons per case matched by sex, day of birth, and calendar time. We identified 19 857 persons who committed suicide and 190 058 controls. We found that MI was associated with a marked increased risk of suicide. The risk of suicide was highest within the first month after discharge for MI for patients with no history of psychiatric illness (adjusted rate ratio, 3.25; 95% confidence interval, 1.61 to 6.56) and for patients with a history of psychiatric illness (adjusted rate ratio, 64.05; 95% confidence interval, 13.36 to 307.06) compared with those with no history of MI or psychiatric illness. However, the risk remained high for at least 5 years after MI and when adjusted for stroke, diabetes mellitus, and socioeconomic factors. Our results suggest the importance of screening patients with MI for depression and suicidal ideation. See p 2388.
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Individualized Assessment of Radiation Dose in Patients Undergoing Coronary Computed Tomographic Angiography With 256-Slice Scanning
The dramatic advances in computed tomography (CT) technology over the past decade have facilitated the rapid evolution of coronary CT angiography (CCTA) and have enhanced its diagnostic value in the noninvasive assessment of coronary artery disease. However, concomitant with the rapidly advancing knowledge pertaining to CCTA and the booming availability of the technique have been the ever-increasing concerns for the patient doses and cancer risks associated with CCTA. Unfortunately, incomplete and contradicting data, attributed partly to the unceasing technology changes, have served to heighten confusion. This study provides estimates of organ doses (based on a novel methodology using patient-specific phantoms) and projected life attributable risks of radiogenic cancer (based on the BEIR-VII approach) in a clinical patient population undergoing CCTA with a 256-slice system. The cancer life attributable risks from CCTA exposure were found to depend significantly on body habitus and to decrease steeply with age at exposure, whereas lung cancer constitutes the most probable detriment for both genders. The recent introduction of wide-detector CT systems in clinical practice has facilitated the routine use of prospectively ECG-gated CCTA. With this technique, the life attributable risks of cancer incidence associated with CCTA exposure were estimated to be as low as 1 in 4000 women and 1 in 13 500 men. These estimated life attributable risks of malignancy may inconsequentially increase lifetime intrinsic cancer risks and compare favorably with hypothetical cancer risks resulting from exposures from alternative imaging tests or screening procedures estimated for the identical patient cohort. Regardless, however, of the scant associated life attributable risks, CCTA exposure should be always carefully considered and clinically justified. See p 2394.
Myocardial Perfusion Scans: Projected Population Cancer Risks From Current Levels of Use in the United States
This article provides population-based estimates of lifetime cancer risk from nuclear myocardial perfusion scans and other cardiac imaging tests for comparison. Positron emission tomography and dual-isotope scans have the lowest and highest radiation exposures, respectively. Cancer risks are low, ranging from 2 cancers per 10 000 scans (95% uncertainty interval, 1 to 5) for ammonia-13 cardiac positron emission tomography to 25 cancers per 10 000 scans (95% uncertainty interval, 9 to 58) for dual-isotope studies. However, because of widespread use of nuclear myocardial perfusion studies (9.1 million scans per year in the United States), it is possible that 7400 additional future cancers could be related to these scans. These risk estimates depend on several assumptions, including the assumption that the cancer risk and radiation dose have a linear no-threshold relationship even at low doses and that the life expectancy for individuals undergoing the scans is similar to that of the general population. The clinician should be familiar with the indications for nuclear myocardial perfusion studies and order scans in accordance with the American Heart Association/American College of Cardiology appropriateness criteria guidelines. In the future, newer technologies with lower radiation exposure and adequate sensitivity and specificity for disease detection may be preferred. See p 2403.
The sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial
Secretory phospholipase A 2 (sPLA 2 ) has been implicated in promoting the inflammatory processes associated with atherosclerosis. Furthermore, sPLA 2 levels increase after percutaneous coronary intervention (PCI), with higher levels being associated with worse long-term outcome. Inhibitors of sPLA 2 have been shown to reduce experimental ischemia/reperfusion injury. The possibility that sPLA 2 inhibition could reduce myocardial injury after elective percutaneous coronary intervention was thus intriguing. In the sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) randomized placebo controlled trial, we tested the hypothesis that varespladib, a selective inhibitor of the sPLA 2 -IIa, sPLA 2 -V, and sPLA 2 -X isoforms, would reduce the occurrence of elevation of troponin I or creatine kinase-MB above the upper limit of normal within 24 hours after percutaneous coronary intervention when administered at a dose of 500 mg twice daily from 3 to 5 days before and up to 5 days after the procedure. Treatment with varespladib profoundly inhibited sPLA 2 but did not reduce postprocedural rise in biomarkers. Furthermore, elevation of creatine kinase-MB to twice the upper limit of normal occurred significantly more frequently in the varespladib group than in the placebo group. It is possible that this was a chance finding. However, different sPLA 2 inhibitors may potentially have different effects on platelet activation and arachidonic acid/prostaglandin pathways. Varespladib is not known to interact with these pathways adversely. However, as development of this agent moves into phase III acute coronary syndrome trials, our data suggest that further surveillance is warranted to ensure not only that the agent can stabilize the chronic inflammatory milieu of the atherosclerotic vascular wall but also that it is safe and efficacious during acute myocardial ischemia. See p 2411.
Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their Long-Term Benefits for Myocardial Repair
Heart failure after a myocardial infarction remains a significant cause of mortality. Many have advocated stem cell therapy to prevent the progression of adverse events, but initial clinical trials did not reproduce the extensive benefits reported in preclinical animal trials. Compared with stem cells from young, healthy individuals, cells derived from elderly patients were found to have a limited ability to restore cardiac function in nonreactive animals. This diminished regenerative capacity of the older patients' stem cells might partially explain the limited benefits of stem cell therapy. Allogeneic mesenchymal stromal cells (MSCs) are an enriched population of cells with advanced therapeutic properties. Allogeneic MSCs offer a source of young, healthy, highly regenerative stem cells for implantation into the postinfarct myocardium. However, it is unclear whether these cells can avoid immune surveillance and engraft in the heart, in part because most preclinical assessments of allogeneic MSC therapy were restricted to the first 8 to 12 weeks after cell implantation. This study included a 6-month-long evaluation of outcomes after allogeneic MSC therapy. We found that, although MSCs are immunoprivileged and can engraft in the heart and improve cardiac function early after implantation, they acquire an immunogenic phenotype and are immune rejected later, after they differentiate into specialized cells. Our findings provide an explanation for the diverse responses to allogeneic MSCs reported in previous studies and caution that these cells appear to have only short-term clinical benefits for the heart. Modifying the late immunogenic phenotype of MSCs may produce prolonged benefits after implantation. See p 2419.
